HUAKANG BIOMED (08622) has released its annual results for the period ending December 31, 2025. The group reported revenue of 28.282 million yuan, representing an increase of 11.53% compared to the previous year. The loss attributable to the company's owners was 5.006 million yuan, which widened by 20.39% year-on-year. The basic loss per share was 1 cent.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.